Sino Biopharmaceutical has launched a new global brand, SBP Group, as the China-based drugmaker moves to expand internationally through in-house research, acquisitions, licensing deals and partnerships.
The company announced the new identity during its interim results meeting. SBP stands for “Science, Breakthroughs and Patients,” a framework the company said reflects its mission of “Science for a Healthier World.”
The rebrand is intended to mark Sino Biopharmaceutical’s evolution from a domestic biopharmaceutical company into a global innovator. Its international strategy is centered on product globalization, through development and acquisition of innovative medicines, and business globalization, through alliances and direct commercial expansion in selected markets.
Sino Biopharmaceutical said 2026 is the first year of executing its globalization strategy. The company is investing in global talent, organizational capabilities and infrastructure as it seeks to make medicines developed in China available internationally and bring therapies developed elsewhere to the Chinese market.
Chairwoman Theresa Tse said the company plans to work with global partners to accelerate the worldwide development and availability of innovative medicines from China. She said SBP Group will use its artificial intelligence-driven, integrated research and development platform to pursue scientific advances intended to benefit more patients.
The company has completed four out-licensing transactions with multinational pharmaceutical companies, generating aggregate upfront payments exceeding $1 billion and potential deal value of more than $7 billion. It has also completed more than 30 merger-and-acquisition, licensing and strategic partnership transactions.
Among its 2026 deals, Sino Biopharmaceutical granted Sanofi exclusive rights to rovadicitinib, a dual JAK/ROCK inhibitor, in a transaction valued at up to $1.53 billion. It also granted AstraZeneca exclusive rights to TQC3721, an inhaled PDE3/4 inhibitor being developed for chronic obstructive pulmonary disease, in a deal valued at up to $1.9 billion.
The company said these transactions support its effort to build a global pipeline of innovative assets while expanding its international commercial operations. The SBP Group identity will serve as the unified brand for that strategy, tying the company’s scientific research, business development and patient-focused objectives together as it pursues a wider global presence.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!